Focus: Attovia Therapeutics is a public-stage biotechnology company leveraging a proprietary biparatopic nanobody platform focused on immunology. The company is early-stage with two Phase 1 programs in atopic dermatitis.
Profile data last refreshed 14h ago · AI intelligence enriched 2mo ago
Stable — net -3 jobs in 30d
2 added, 5 removed. Backfill posture.
High-risk, early-stage opportunity best suited for researchers betting on platform technology rather than career stability or near-term impact.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Attovia Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Attovia Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Attovia Therapeutics, Inc. (ATTO) Stock Price & News - Syfe
Attovia Therapeutics, Inc. (ATTO) Stock Price & News Syfe
Attovia Therapeutics, Inc. (NASDAQ:ATTO) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Attovia Therapeutics, Inc. (NASDAQ:ATTO) Receives Consensus Recommendation of "Moderate Buy" from Brokerages MarketBeat
Attovia Therapeutics, Inc.'s (NASDAQ:ATTO) Quiet Period To End on September 14th - MarketBeat
Attovia Therapeutics, Inc.'s (NASDAQ:ATTO) Quiet Period To End on September 14th MarketBeat
Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update - GlobeNewswire
Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update GlobeNewswire
Goldman to sell $2.2M in Attovia Therapeutics (ATTO) stock - Stock Titan
Goldman to sell $2.2M in Attovia Therapeutics (ATTO) stock Stock Titan
Goldman units log Attovia (NASDAQ: ATTO) 500K-share buy and equity swap trades - Stock Titan
Goldman units log Attovia (NASDAQ: ATTO) 500K-share buy and equity swap trades Stock Titan
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo